Search 

Immunimed Inc is a clinical-stage Biopharmaceutical company developing innovative egg-derived, oral potclonal antibody therapy to treat gastro-enteric infections/diseases. Our lead product IMM-001 targets super bug, Clostridium difficile, leading cause of hospital-acquired infections.

Currently is Phase II ready with remarkable clinical response in Proof on Concept multi-center clinical studies.  Phase II clinical study is planned for Q2 2015.

Immunova is a startup with  an IP portfolio licensed from Yale and the Johns Hopkins Universities.

Immunova's technology platform has a unique capability to deliver one or more drugs to the tumor/disease microenvironment. The drugs can be proteins, small molecules or nucleic acids. The delivery platfrom has demonstatable advantages over other delivery systems. The technology has applications in oncology and inflammation.

The company's lead asset is positioned in oncology. IMM-01, consists of two drugs that (a) undermine the tumor micorenvironment and (b) increase anti-tumor cell mediated immunity. This asset is capable of curing mice of metastatic disease. Further, it significantly enhances the activites of immune checkpoint inhibitors. It is non toxic.

The company is seeking investment and R&D partners. Immunova has defined the path to a Phase I/IIa multidose trial which could initiate within 15 months of funding. Immunova is also seeking partners who wish to validate this platform in oncology and inflammation.

Immusoft’s mission is to develop a breakthrough platform for delivering targeted medicines — programming a patient’s own cells to become miniature drug factories.

Our technology instructs a patient's cells to constantly secrete gene-encoded medicines (biologics). It will enable new treatments by solving current delivery limitations and production challenges. We are initially targeting orphaned diseases. 

Immusoft’s platform can program cells to continually produce and secrete therapeutic proteins and rare antibodies that have been impossible to elicit with a vaccine. This approach makes possible treatments that are otherwise impractical due to short halflife, injection site reactions, production challenges or a small market size. It offers many of the benefits of traditional approaches and modern gene therapies with less risk and greater control.

Immusoft has received grants from the National Institutes of Health and Peter Thiel's Breakout Labs as well as support from private investors, including the former head of preclinical development at Seattle Genetics. We have an exclusive license option on our core technology from Caltech and have filed two additional patents covering our extensive modifications to the technology.

ISP technology could replace a lifetime of infusions with a patient’s own drug-producing cells.

Small biotechnology companies are developing half of all future medicines, some of which may not reach patients due to lack of funding from traditional investors.

Although health-related charities received more than $31B in contributions in 2013, many of the charities which support research do not work with for-profit biotech companies. They predominantly fund academic and non-profit institutions which typically conduct early research and discover around 10% of new medicines (for-profit companies discover the remaining 90%).

Impatient is a new kind of health-related charity. We will only fund medical trials with small biotech companies.  

Our scientific advisors will select promising, unfunded, medical treatments. You choose which treatment to support and 100% of your donation is spent on testing.

If the treatment is successful, 100% of the future royalty that Impatient receives from the biotech company will support access to new medicines for people who cannot afford them.  

IMS Health Capital (IMSHC) is a niche life-science focused investment bank which manages financing transactions, and advises on M&A and licensing/partnering transactions.

IMS Health Capital (IMSHC) is a fully owned subsidiary of IMS Health, Inc. (www.imshealth.com) and affiliated with IMS Consulting Group (www.imscg.com).

IMSHC has privileged access to a vast array of IMS Health’s resources and connections and can help prepare a compelling value proposition and put you in touch with the right interested parties.  Our team has extensive life-science industry experience and can provide support at any and all stages of the transaction process.  Unlike most investment banks or business development consultants, IMSHC has immense strategic partnering capabilities and can work with companies on both partnering and financing efforts.  Given our unique positioning and access to a vast array of information and relationships, we see a high volume of opportunities.

IMSHC is a SEC/FINRA licensed broker dealer and a wholly owned subsidiary of IMS Health, Inc.  IMS Health Inc. is publicly traded on the NYSE under the ticker “IMS”, and is the world’s leading information, services and technology company in the Life Sciences sector.  Customers of IMS Health’s data and consulting services include most of the top names in pharmaceutical, medical device and consumer health manufacturers and distributors, providers, payers, government agencies, policymakers, researchers and the financial community (www.imshealth.com).

ImStar Therapeutics is a private biotechnology company headquartered in Vancouver that is developing new approaches to treat patients with Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease.

The company is developing compounds directed at a proprietary new therapeutic target for ALS discovered by co-founder Dr. Jean-Pierre Julien called TANA (i.e. TDP-43 Associated NF-kB Activation). The lead drug candidate, IMS-088, is a novel small molecule compound targeting the NF-kB activation pathway currently in preclinical development for ALS.

IMS-088 is the first in a series of novel compounds derived from withaferin A (WA), a natural withanolide isolated from the leaves of the winter cherry plant (withania somnifera).  In preclinical animal studies, WA showed promise but lacked suitable pharmacologic characteristics to be developed as a therapeutic drug.

Therapeutics targeting the TANA pathway could treat multiple neurodegenerative diseases expressing TDP-43 pathology such as ALS, Alzheimer's, Parkinson's and Dementia.

TAR DNA-binding protein 43 (TDP-43) was recently identified as a major disease-associated protein in ALS. Under normal conditions, TDP-43 regulates RNA and is predominantly localized in the nucleus. However, in ALS-affected neuronal cells the protein is misprocessed resulting in aggregation in the cytoplasm and a loss of motor function.

A recent discovery has shown that, in patients with ALS, TDP-43 unexpectedly associates with and activates nuclear factor-κB (NF-κB), an inflammation-regulating protein. This leads to exaggerated immune responses and motor neuron destruction. Inhibition of the pathway in an ALS disease model produced substantial improvements in disease and motor function illustrating this is an important new drug target.

Novel Withanolides

ImStar chemists have designed novel withanolides related to WA that have superior drug like properties. IMS-088 is the lead drug candidate in this series that is currently being developed for ALS. These compounds are covered by a new composition of matter patent filing.

TANA Inhibitors

ImStar is also developing various approaches to block TDP-43 activity and has identified novel single chain variable domain antibody fragments (scFv) that inhibit TDP-43 and block it's associated NF-kB activation.